Allergy Relief 24hr (Levocetirizine Dihydrochloride)
Brand Names: Allergy Relief 24hr
Methodology & AI Transparency ⓘ
Allergy Relief 24hr (Levocetirizine Dihydrochloride) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary histamine-1 receptor antagonist presentation registered by VELOCITY PHARMA LLC, Allergy Relief 24hr supplies active moiety Levocetirizine Dihydrochloride (cross-referenced at /meds/levocetirizine-dihydrochloride) in 5 mg/1 Tablet; 5 mg/1 Tablet, Film Coated (NDC 76168-501, 71205-988; SPL 2024-10-29).
- 2 Real-world patient consensus: Registered under RxNorm 855172-B76168501 and SPL 2024-10-29, pairing Allergy Relief 24hr packaging with active ingredient Levocetirizine Dihydrochloride.
- 3 Typical cash cost range: 30-day cash pricing ranges from $12.18 discount cash to $34.50 walk-in retail (NADAC $0.0511/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Allergy Relief 24hr (Levocetirizine Dihydrochloride)): pruritus (2.6%), nausea (9%), headache (7.3%).
Ask our AI Specialists anything about Allergy Relief 24hr (Levocetirizine Dihydrochloride)
Allergy Relief 24hr (Levocetirizine Dihydrochloride) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary histamine-1 receptor antagonist presentation registered by VELOCITY PHARMA LLC, Allergy Relief 24hr supplies active moiety Levocetirizine Dihydrochloride (cross-referenced at /meds/levocetirizine-dihydrochloride) in 5 mg/1 Tablet; 5 mg/1 Tablet, Film Coated (NDC 76168-501, 71205-988; SPL 2024-10-29). Clinical prescribing and dispensing guidelines focus on Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy,.
The active constituent inside Allergy Relief 24hr—Levocetirizine Dihydrochloride—functions as a targeted histamine-1 receptor antagonist agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Levocetirizine Dihydrochloride, Allergy Relief 24hr (registered by VELOCITY PHARMA LLC, SPL 2024-10-29) specifies proprietary packaging (76168-501, 71205-988) and 5 mg/1 Tablet; 5 mg/1 Tablet, Film Coated quality controls alongside a $0.0511/unit NADAC acquisition baseline.
With Biphasic clearance with 8–16 hr terminal t½ under Allergy Relief 24hr (Levocetirizine Dihydrochloride) maintenance residence kinetics and Systemic oral bioavailability of roughly 66%–78% following first-pass transit bioavailability, Allergy Relief 24hr (Levocetirizine Dihydrochloride) undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (allergy relief 24hr (levocetirizine dihydrochloride)) and establishes therapeutic activity over initial pharmacodynamic onset within 1–2 hrs (peak cmax) for allergy relief 24hr (levocetirizine dihydrochloride).
Standard adult regimens span 5 mg/1 Tablet, 5 mg/1 Tablet, Film Coated, 5 mg/1 Tablet, Coated, .5 mg/mL Solution, 2.5 mg/5mL Solution. Prescribers screen specifically against documented intolerance or hypersensitivity reaction involving levocetirizine dihydrochloride (histamine-1 receptor antagonist); concurrent restricted medications flagged in section 4/7 of the allergy relief 24hr (levocetirizine dihydrochloride) dailymed monograph (855172-b76168501), while community micro-logs most frequently note nausea (9% of reports), headache (7.3% of reports), dizziness (5.2% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Allergy Relief 24hr (Levocetirizine Dihydrochloride) (histamine-1 receptor antagonist).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Allergy Relief 24hr (Levocetirizine Dihydrochloride) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Levocetirizine Dihydrochloride (histamine-1 receptor antagonist)
- Concurrent restricted medications flagged in Section 4/7 of the Allergy Relief 24hr (Levocetirizine Dihydrochloride) DailyMed monograph (855172-B76168501)
Logged Side-Effect Incidence (18 Reports)
Allergy Relief 24hr (Levocetirizine Dihydrochloride) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Allergy Relief 24hr (Levocetirizine Dihydrochloride))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Check Your Medicine Cabinet: WinCo Foods LLC Issues Allergy Alert on Undeclared Sesame in Hoagie Rolls Indexed from FDA Drug Recalls (2026-10-22) by DotMD's 2-hour clinical surveillance pipeline. FDA Drug Recalls • 2026-10-22 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-3221894050 ↗ |
| Check Your Medicine Cabinet: Pan Pepin Inc. Issues Allergy Alert of Para Bien Al Grano Due to Undeclared Sesame Indexed from FDA Drug Recalls (2026-10-13) by DotMD's 2-hour clinical surveillance pipeline. FDA Drug Recalls • 2026-10-13 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-2875230887 ↗ |
| Can This Approach Help? Inside the Latest Research on Oral desensitization therapy for peanut allergy induces dynamic changes in Oral desensitization therapy with AR101 leads to decreased basophil sensitivity to peanut and reshapes peanut-reactive T effector cell responses supporting its potential as an immunomodulatory therapy. Allergy • 2022-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35266148 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of epicutaneous immunotherapy in children with peanut allergy The results suggest that 12 months of treatment with VP250 was effective in desensitizing children with peanut allergy aged 1 to 3 years, with no difference in efficacy and a favorable safety profile, regardless of the... Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40204253 ↗ |
Allergy Relief 24hr (Levocetirizine Dihydrochloride) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0511/unit (~$1.53/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $12.18 / mo | View logs ↓ |
Allergy Relief 24hr (Levocetirizine Dihydrochloride) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Allergy Relief 24hr (Levocetirizine Dihydrochloride) RxNorm Concept ID | 855172-B76168501 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0511 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.18 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Allergy Relief 24hr (Levocetirizine Dihydrochloride) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Allergy Relief 24hr (Levocetirizine Dihydrochloride): FDA labeling (2024-10-29, NDC 76168-501), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Allergy Relief 24hr (Levocetirizine Dihydrochloride) community threads and patient logs by age, biological sex, dosage, and treatment duration.